C-Statin, a natural compound from bindweed, appears to inhibit abnormal blood vessel growth by up to 73% and abnormal cell growth by up to 96.8%, while promoting the immune system, a trilogy current drugs seem unable to achieve.
C-Statin (™) contains a patented Proteoglycan Molecule (PGM) from a ubiquitous plant, field bindweed, or Convolvulus arvensis, that is a potent angiogenesis inhibitor. It may also be obtained from Morning Glory. PGM has been tested for anti-angiogenic, immunostimulatory, and antineoplastic activity by members of the Riordan Clinic in Arizona,
Studies have demonstrated PGM to be 100 times stronger than shark cartilage, which used to be recommended by healthcare professionals to block angiogenesis. In the research (1) C-Statin has no recorded adverse side effects - it is non-toxic. PGMs were demonstrated to have significant anti-angiogenic and immunostimulatory effects. C-Statin has been shown to inhibit new blood vessel growth up to 73% and abnormal cell growth up to 96.8%.
Recruitment of new blood vessels plays a crucial role in tumour survival and growth. Much research is currently investigating angiogenesis, and inhibitors are currently being investigated as anti-tumor agents. For example in NSCLC, EGFR mutation promoted VEGF (vascular Epithelial Growth Factor) over-expression, and this increase was thought to play a role in supporting angiogenesis. But blocking EGFR mutations, and downregulating VEGF alone seems to be not enough to inhibit tumour growth. Cutting the blood supply just builds hypoxia - a normal low to zero oxygen state of tumours (2). The anti-EGFR drugs need to be combined with antineoplastic chemotherapy drugs that can attack a hypoxic tumour.
C-Statin is available in capsules as a food supplement. It supports normal angiogenesis, restricts abnormal angiogenesis in cancer and has anti-tumour properties. It does both jobs, as evidenced in several studies.
For example, in a chicken egg chorioallantoic membrane assay, PGM inhibited new blood vessel growth in a dose-dependent manner. Results were 18, 55, and 73 per cent inhibition at concentrations of 50, 100, and 200 mcg, respectively.
For example, PGM also significantly inhibited tumour growth in vivo - using mouse models with fibrosarcoma and lung carcinoma at 250-1000 microgram daily doses for 14 days. Inhibition was 54-77% depending upon weight compared to controls, or up to 96.8 per cent by cellular composition.
PGM also stimulates the immune system inducing lymphocyte growth in a dose dependent manner. The ability of PGM-treated phagocytes to phagocytose yeast cells was 85% greater than controls.
The PGM could be taken in any fashion - intravenous; intraperitoneal; subcutaneous; and oral.
The researchers concluded that PGM is a potent angiogenesis inhibitor, with immunostimulatory activity in vitro, and anti-tumor activity in vivo.
They recommended further investigation.
Go to: 12 ways to boost your immune system
*****
References
-
Riordan NH, Meng X, Riordan HD. http://www.arc-nutrition.com/wp-content/uploads/2016/02/pgm-paper.pdf;
-
Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer; Wentao Tian et al; Onco Targets Ther. 2020; 13: 12113–12129 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699985/